Board of Directors

As President and Chief Executive Officer of Zenith, Mr. McCaffrey has 40+ years of corporate management experience including nearly 25 years in drug discovery and development. Don’s expertise in corporate operations has attracted an international team of experts, including world renowned opinion leaders in oncology. He has facilitated many high-profile collaborations and partnerships with leading academic, industry, and governmental organizations including Pfizer, Merck & Co, Eli Lilly & Company, Newsoara BioPharma, National Cancer Institute, University of California San Francisco and the Dana-Farber Cancer Institute.

Additionally, Don serves as President and CEO of Resverlogix (TSX: RVX), a late-stage clinical biotechnology company, developing advanced epigenetic therapies for the treatment of chronic cardio-metabolic disease. Resverlogix’s lead candidate, apabetalone, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, a first for a major cardiovascular indication. Zenith was spun out of Resverlogix in 2013.

Don is passionate about supporting local non-profit organizations, including: the Libin Cardiovascular Institute of Alberta, Juvenile Diabetes Research Foundation, Sanofi Biogenius Canada (MindFuel), United Way, Mount Royal University Foundation, Alberta Children's Hospital, Edge School Foundation, Education Matters, Calgary Urban Project Society Literacy Program, Movember Foundation, and Enbridge Ride to Conquer Cancer.

Mr. McNeill has nearly 30 years of experience in manufacturing and technology organizations, both large and small, with experience in M&A, raising capital in public equity markets and managing complex operations around the globe. McNeill is the CEO & CFO at RTDS Technologies, a global provider of real time digital simulators to the power systems industry. Kelly has also served as Executive Vice President, Finance and Administration & CFO of IMRIS, as well as CFO of Resverlogix. Prior thereto, he held senior financial positions with two multinational companies: General Manager of the Canadian operations for Haworth and Vice President of Finance for SMED. Mr. McNeill holds a Masters of Accountancy and a Bachelor of Commerce (Honours), and is a Chartered Professional Accountant/Chartered Accountant. He also serves on the Board of Directors and Audit Committee of Resverlogix.

Dr. Thompson is an experienced biotechnology founder and executive having served in multiple CEO roles for public companies over the past 25 years.  He has also served as Chairman, Director, and an Audit Committee member on the boards of directors for numerous public companies (NASDAQ, TSX and CDNX), and has served in similar roles for private company boards and industry groups (including Chairman and Chairman Emeritus of BIOTECanada).  He has taken companies public on the TSX, NASDAQ, and the former Alberta Stock Exchange, and has also led successful cross-listings (from the TSX to the NASDAQ). Dr. Thompson holds a PhD in Microbiology and Immunology from Western University. Prior to entering the private sector, his research affiliations included working with NASA, the Canadian Space Agency, the United Nations, Colorado State University, and the University of Alberta.

Dr. Wong is Co-founder of Resverlogix, and previous served as the company’s Chief Scientific Officer. Dr. Wong serves as Professor of Medicine, University of Calgary, a clinician and scientist who specializes in endocrinology, internal medicine, molecular biology, gene/cell therapy and regulation. His numerous academic accomplishments include over 300 published works, including extensive research in the field of epigenetics. Dr. Wong has served as a medical consultant to Abbott Laboratories, Amgen, AstraZeneca, B.I., Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck, Sanofi, and Solvay Pharmaceuticals in the areas of diabetes mellitus, thyroid disease, testosterone treatment and in the development of cholesterol lowering drugs. In addition to serving as a director for Zenith, he is a member of the Scientific Advisory Board at Sernova Biotherapeutics. Dr. Wong’s academic record includes an Undergraduate B.Sc., a Masters Degree in Medical Biochemistry, and a Medical Degree from the University of Calgary.

Mr. Zuerblis brings over 30 years of proven leadership expertise in building fully integrated biopharmaceutical organizations and has an established track record of managing complex commercial and research organizations, raising capital, overseeing multifaceted M&A transactions, and directing investor relations. Mr. Zuerblis was formerly Executive Vice President and Chief Financial Officer of Savient Pharmaceuticals. Prior to joining Savient, Mr. Zuerblis served as Chief Financial Officer and Senior Vice President at ImClone Systems where he was responsible for the strategic planning and leadership of financial operations. He helped lead all aspects of the sale of the company to Eli Lilly and Company. Mr. Zuerblis also served as Chief Financial Officer and Corporate Controller of Enzon Pharmaceuticals. During his 14-year tenure, Enzon transformed from an early stage biotechnology company into a fully integrated biopharmaceutical company with five marketed products, including the first three FDA approved products using PEGylation technology. He began his career at KPMG where he held management positions of increasing responsibility over a 10-year period. Mr. Zuerblis earned his Bachelor of Science in Accounting from Seton Hall University and is a certified public accountant in the State of New Jersey. He also serves on the Board of Directors and audit committee of Resverlogix.